Skip to main content

Table 5 Breast and ovarian cancers occurring after the family was referred to the genetics centre.

From: Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

  Number of women Years f/u (Breast ca) Cancers Rate (%/Year) Number of women Years f/u (ovarian ca) Cancers Rate
BRCA1 Carriers 256 1522.33 65 4.27 403 2256.13 37 1.64
BRCA1 FDR unknown 341 1988.07 13 0.65 355 2049.42 6 0.29
BRCA1 Index 87 399.49 37 9.3 194 977.35 24 2.5
BRCA1 Carriers less index 159 1122.33 28 2.5 209 1278.78 13 1.01
BRCA2 Carriers 210 1210.41 61 5.0 363 2235.14 12 0.54
BRCA2 FDR unknown 324 2096.93 12 0.57 345 2187.04 4 0.19
BRCA2 Index 66 285.59 36 12.6 175 966.69 9 0.93
BRCA2 Carriers less index 144 924.82 25 2.7 363 1268.45 3 0.24
  1. Censored if affected with relevant cancer prior to date of referral and at RRS, relevant cancer diagnosis, or date of last follow up.
  2. The index case was used to identify the mutation. Women were censored at time of risk reducing surgery.